Research and experimental development on natural sciences and engineering
VAXXINOVA NORWAY AS
Revenue 2025
NOK 17.7m
Operating profit
NOK −35.5m
Equity
NOK 893,000
Incorporated
2010
Employees
23
Share capital
NOK 100,000
Key figures · 2025
Current ratio
2.02
Equity ratio
1.1%
Key figures over time · 2025
| Key figures | 2025 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -201.1% | |
| Net margin (%%) | -138.9% | |
| Return on assets (%%) | -45.2% | |
| Likviditet | ||
| Current ratio | 2.02 | |
| Working capital | 12.7m | |
| Soliditet | ||
| Equity ratio (%%) | 1.1% | |
| Debt-to-equity ratio | 87.16 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.